IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one ratings firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $255.71.

A number of research analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. BTIG Research lowered their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st.

IQVIA Trading Down 0.7 %

IQVIA stock opened at $204.54 on Friday. The business has a 50-day simple moving average of $199.71 and a two-hundred day simple moving average of $221.06. The company has a market cap of $37.12 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently modified their holdings of IQV. FMR LLC lifted its holdings in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of IQVIA during the third quarter worth approximately $147,683,000. JPMorgan Chase & Co. increased its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, KBC Group NV grew its holdings in IQVIA by 68.5% in the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after buying an additional 250,458 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.